persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC).

Nicholas C. Turner,Komal Jhaveri,Aditya Bardia,Naoki Niikura,Véronique Diéras,Carlos Barrios,Seock-Ah Im,Volkmar Mueller,Meritxell Bellet,Ching-Wei Chang,Graham Ross,Monika Patre,Sherene Loi

persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC).

2021

Nicholas C. Turner
Komal Jhaveri
Aditya Bardia
Naoki Niikura
Véronique Diéras
Carlos Barrios
Seock-Ah Im
Volkmar Mueller
Meritxell Bellet
Ching-Wei Chang
Graham Ross
Monika Patre
Sherene Loi

TPS1103Background: Modulating estrogen synthesis and/or ER activity is the mainstay of treatment for pts with ER+ BC. Despite substantial progress, many pts experience relapse during/after adjuvant...

Keywords:

Internal medicine
Medicine
Palbociclib
locally advanced
Letrozole
Oncology
in patient
HER2 negative
Adjuvant
Estrogen receptor
Breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations